PF-Atlas › Clinical Trials › NCT03344159
Spironolactone Therapy in Chronic Stable Right HF Trial
Spironolactone · Phase 4
Registry ID
NCT03344159
Phase
Phase 4
Status
Completed
Drug / intervention
Spironolactone
Sponsor
Ottawa Heart Institute Research Corporation
Start
2018-04-01
Enrollment
15
Locations
1
About this trial
The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in patients with chronic right heart failure.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03344159 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.